Astellas Pharma has announced the approval of VEOZA (fezolinetant) 45mg in Singapore, marking it as the first non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause. This approval follows the BRIGHT SKY programme, which involved three Phase 3 clinical trials with over 3,000 participants across Europe, the US, and Canada.
VMS, commonly known as hot flushes and night sweats, affects over 50% of women globally and 19% of women in Singapore. The imbalance between oestrogens and neurokinin B during menopause leads to these symptoms. A 2023 study highlighted that more than 60% of Singaporean women experience at least one moderate to severe menopausal symptom, with VMS being a significant concern.
Aycin Oguz, general manager for Malaysia and Singapore, stated, “This approval marks yet another significant milestone for our company, fezolinetant and women’s health.” Rebecca Chng, head of Medical Affairs at Astellas Pharma Singapore and Malaysia, added, “VEOZA represents a meaningful advancement in how we address vasomotor symptoms.”
Fezolinetant was initially approved by the US Food and Drug Administration in May 2023. With its recent authorisation in Singapore, women are encouraged to consult healthcare providers to determine if VEOZA is suitable for them.
This development not only expands treatment options for menopausal women but also underscores Astellas’ commitment to addressing unmet medical needs.
“`
